翰森制药(03692.HK) 公布,于11月1日,集团自研B7-H3靶向抗体-药物偶联物注射用HS-20093获国家药监局批准纳入突破性治疗药物,拟定适应症为经标准一线治疗后进展的广泛期小细胞肺癌。(ha/da)(港股报价延迟最少十五分钟。沽空资料截至 2024-11-01 16:25。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.